Parv Chapani
Research Subjects
Parv Chapani has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
Alexandra E. Kovach
15Vanderbilt Ingram Cancer Center, Nashville, TN
1 shared publicationAlexandra M. Donovan
12Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH
1 shared publication- Alina S. Gerrie
University of British Columbia and BC Cancer, Vancouver, Canada
1 shared publication - Amitkumar Mehta
Medicine, University of Alabama at Birmingham, Birmingham, Alabama
1 shared publication Andreas Klein
21Division of Hematology/Oncology, Tufts University, Boston, MA
1 shared publication- Andrew M. Evens
Rutgers Cancer Institute, New Brunswick, NJ
1 shared publication
Latest Publications
- Open Access
- 13 December 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (24) , 7393-7401
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma
Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma; data indicate that blastoid and pleomorphic variants have a poor prognosis. We report characteristics and outcomes of patients with blastoid/pleomorphic variants of MCL. We retrospectively studied adults with newly diagnosed MCL treated from 2000 to 2015. Primary objectives were to describe progression-free survival (PFS) and overall survival (OS). Secondary objectives included characterization of patient characteristics and treatments. Of the 1029 patients with MCL studied, a total of 207 neoplasms were blastoid or pleomorphic variants. Median follow-up period was 82 months (range, 0.1-174 months); median PFS was 38 months (95% confidence interval [CI], 28-66) and OS was 68 months (95% CI, 45-96). Factors associated with PFS were receipt of consolidative autologous hematopoietic transplantation (auto-HCT; hazard ratio [HR], 0.52; 95% CI, 0.31-0.80; P < .05), MCL International Prognostic Index (MIPI) intermediate (HR, 2.3; 95% CI, 1.2-4.3; P < .02) and high (HR, 3.8; 95% CI, 2.0-7.4; P < .01) scores, and complete response to induction (HR, 0.29 (95% CI, 0.17-0.51). Receipt of auto-HCT was not associated with OS (HR, 0.69; 95% CI, 0.41-1.16; P = .16) but was associated with MIPI intermediate (HR, 5.7; 95% CI, 2.5-13.2; P < .01) and high (HR, 10.8; 95% CI, 4.7-24.9; P < .01) scores. We report outcomes in a large cohort of patients with blastoid/pleomorphic variant MCL. For eligible patients, receipt of auto-HCT after induction was associated with improved PFS but not OS. Higher MIPI score and auto-HCT ineligibility were associated with worse survival.
- 13 December 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (24) , 7393-7401
Open AccessOutcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma
Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma; data indicate that blastoid and pleomorphic variants have a poor prognosis. We report characteristics and outcomes of patients with blastoid/pleomorphic variants of MCL. We retrospectively studied adults with newly diagnosed MCL treated from 2000 to 2015. Primary objectives were to describe progression-free survival (PFS) and overall survival (OS). Secondary objectives included characterization of patient characteristics and treatments. Of the 1029 patients with MCL studied, a total of 207 neoplasms were blastoid or pleomorphic variants. Median follow-up period was 82 months (range, 0.1-174 months); median PFS was 38 months (95% confidence interval [CI], 28-66) and OS was 68 months (95% CI, 45-96). Factors associated with PFS were receipt of consolidative autologous hematopoietic transplantation (auto-HCT; hazard ratio [HR], 0.52; 95% CI, 0.31-0.80; P < .05), MCL International Prognostic Index (MIPI) intermediate (HR, 2.3; 95% CI, 1.2-4.3; P < .02) and high (HR, 3.8; 95% CI, 2.0-7.4; P < .01) scores, and complete response to induction (HR, 0.29 (95% CI, 0.17-0.51). Receipt of auto-HCT was not associated with OS (HR, 0.69; 95% CI, 0.41-1.16; P = .16) but was associated with MIPI intermediate (HR, 5.7; 95% CI, 2.5-13.2; P < .01) and high (HR, 10.8; 95% CI, 4.7-24.9; P < .01) scores. We report outcomes in a large cohort of patients with blastoid/pleomorphic variant MCL. For eligible patients, receipt of auto-HCT after induction was associated with improved PFS but not OS. Higher MIPI score and auto-HCT ineligibility were associated with worse survival.
- 21 November 2022
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 64 (1) , 1-3
Validation of an administrative coding algorithm for the identification of individuals with amyloid light chain amyloidosis using administrative data
Amyloid light chain (AL) amyloidosis is a rare plasma cell disease in which AL protein deposits form throughout the body, with the heart, and kidney being the most commonly affected organs [1,2]. I...
- 21 November 2022
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 64 (1) , 1-3
Validation of an administrative coding algorithm for the identification of individuals with amyloid light chain amyloidosis using administrative data
Amyloid light chain (AL) amyloidosis is a rare plasma cell disease in which AL protein deposits form throughout the body, with the heart, and kidney being the most commonly affected organs [1,2]. I...
- 1 June 2022
- Published by Elsevier in Clinical Colorectal Cancer
- Vol. 21 (2) , 107-113
Impact of Tumor Location on Patient Outcomes in Small Bowel Cancers
- 1 June 2022
- Published by Elsevier in Clinical Colorectal Cancer
- Vol. 21 (2) , 107-113
Impact of Tumor Location on Patient Outcomes in Small Bowel Cancers